Show simple item record

dc.contributor.authorIJzerman, MJ
dc.contributor.authorBerghuis, AMS
dc.contributor.authorde Bono, JS
dc.contributor.authorTerstappen, LWMM
dc.date.accessioned2018-11-14T12:27:40Z
dc.date.issued2018-12
dc.identifier.citationExpert review of pharmacoeconomics & outcomes research, 2018, 18 (6), pp. 593 - 599
dc.identifier.issn1473-7167
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2937
dc.identifier.eissn1744-8379
dc.identifier.doi10.1080/14737167.2018.1505505
dc.description.abstractIntroduction Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly alternative for serial analysis of tumor progression and heterogeneity to facilitate clinical management. Although a variety of tumor markers are proposed (e.g., free-circulating DNA), the clinical evidence for Circulating Tumor Cells (CTCs) is currently the most developed. Areas covered: This paper presents a health economic perspective of LBs in cancer management. We first briefly introduce the requirements in biomarker development and validation, illustrated for CTCs. Second, we discuss the state-of-art on the clinical utility of LBs in breast cancer in more detail. We conclude with a future perspective on the clinical use and reimbursement of LBs Expert commentary: A significant increase in clinical research on LBs can be observed and the results suggest a rapid change of cancer management. In addition to studies evaluating clinical utility of LBs, a smooth translation into clinical practice requires systematic assessment of the health economic benefits. This paper argues that (early stage) health economic research is required to facilitate its clinical use and to prioritize further evidence development.
dc.formatPrint-Electronic
dc.format.extent593 - 599
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectBreast Neoplasms
dc.subjectDisease Progression
dc.subjectReimbursement Mechanisms
dc.subjectFemale
dc.subjectNeoplastic Cells, Circulating
dc.subjectBiomarkers, Tumor
dc.subjectLiquid Biopsy
dc.titleHealth economic impact of liquid biopsies in cancer management.
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14737167.2018.1505505
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-12
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfExpert review of pharmacoeconomics & outcomes research
pubs.issue6
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume18
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorDe Bono, Johannen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record